In summary, METTL16 drives AML progression and leukemia stem cell maintenance through m6A-dependent modulation of metabolic and transcriptional pathways, establishing it as a key epitranscriptomic regulator and a promising therapeutic target in AML. The gene discussed is METTL16; the disease is acute myeloid leukemia.